Dopamine D2 Receptors in Prefrontal Function: An Optogenetic and Modeling Study

前额叶功能中的多巴胺 D2 受体:光遗传学和建模研究

基本信息

项目摘要

DESCRIPTION (provided by applicant): Dopamine (DA) plays a central role in the function of the prefrontal cortex (PFC). While the majority of dopamine receptors in PFC are D1-type, D2-receptors (D2Rs) play a vital role both as a counterbalance to D1 activation in working memory and in modulating behavior during set-shifting tasks. Additionally, dysfunction of the D2R system has been hypothesized to underlie a number of psychiatric diseases, most notably schizophrenia, and D2Rs are a major target of drug therapies. Recently, with collaborators in the Sohal laboratory, I have studied D2R-expressing neurons in mouse PFC and discovered two major results: (1) The population of D2R-expressing pyramidal cells in layer V PFC is coincident with a previously identified population of thick-tufted, subcortically projecting neuron. (2) Applying D2R agonists to these cells leads to a calcium-activated non-specific ion channel mediated afterdepolarization that is dependent on calcium entry through NMDR receptors and dendritic L-type calcium channels. These findings, taken together with studies showing that thick-tufted PFC neurons form a highly recurrent network in layer V of PFC suggest the following hypothesis: DA can lead to epochs of persistent network activity in D2R-expressing cell networks analogous to the activity that has been observed with D1R activation, and the amount and type of DA stimulation can modulate the stability of patterns of activity in these cells. This hypothesis will be tested through a combination of experimental and computational modeling aims. Experimentally, I will test the precise response of D2R-expressing neurons to synaptic and dopaminergic stimuli using optogenetic techniques to stimulate different types of axon terminals. This data will then be integrated into a biophysical model of networks of D2R-expressing neurons to discover the precise conditions under which persistent activity can occur among these cells and the extent to which patterns of persistent activity are stable against different types of synaptic input. This study will help to illuminate the role of D2R-expressing cells in the function of the PFC by providing an explicit model of these cells. In addition, this model may be used to gain insight into perturbations of normal D2R function that have been hypothesized to underlie psychiatric diseases such as schizophrenia. PUBLIC HEALTH RELEVANCE: Dopamine has an important role in the normal function of the cortex. Dysfunction of the dopamine system is thought to underlie a number of psychiatric diseases including schizophrenia. A detailed model of dopamine's effect on cortical networks could lead to new insights into the diagnosis and treatment of these diseases.
描述(申请人提供):多巴胺(DA)在前额叶皮质(PFC)的功能中起着核心作用。虽然PFC中的大多数多巴胺受体是D1型的,但D2受体(D2Rs)在平衡工作记忆中的D1型激活和在集合转移任务中调节行为方面发挥着至关重要的作用。此外,D2R系统的功能障碍被认为是许多精神疾病的基础,最明显的是精神分裂症,D2R是药物治疗的主要靶点。最近,我与Sohal实验室的合作者研究了小鼠PFC中D2R表达的神经元,发现了两个主要结果:(1)在V层PFC中表达D2R的锥体细胞群与先前发现的粗簇状、皮质下投射神经元群一致。(2)应用D2R激动剂可引起钙激活的非特异性离子通道介导的后去极化,该通道依赖于钙离子通过NMDR受体和树突L型钙通道进入细胞内。这些发现,再加上PFC神经元在PFC的V层形成一个高度重复的网络的研究,提出了以下假设:DA可以在表达D2R的细胞网络中导致持续网络活动的时代,类似于D1R激活所观察到的活动,DA刺激的数量和类型可以调节这些细胞中活动模式的稳定性。这一假设将通过实验和计算建模目标的组合来检验。在实验上,我将使用光遗传学技术刺激不同类型的轴突终末,测试表达D2R的神经元对突触和多巴胺能刺激的准确反应。然后,这些数据将被整合到表达D2R的神经元网络的生物物理模型中,以发现这些细胞之间发生持续活动的确切条件,以及持续活动模式对不同类型突触输入的稳定程度。这项研究将通过提供一个明确的模型,帮助阐明D2R表达细胞在PFC功能中的作用。此外,这个模型可以用来洞察正常D2R功能的扰动,这些扰动被假设为精神分裂症等精神疾病的基础。 与公众健康相关:多巴胺在大脑皮层的正常功能中起着重要作用。多巴胺系统功能障碍被认为是包括精神分裂症在内的许多精神疾病的基础。多巴胺对大脑皮层网络影响的详细模型可能会为这些疾病的诊断和治疗带来新的见解。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Ian Thomas Ellwood其他文献

Ian Thomas Ellwood的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Ian Thomas Ellwood', 18)}}的其他基金

Dopamine D2 Receptors in Prefrontal Function: An Optogenetic and Modeling Study
前额叶功能中的多巴胺 D2 受体:光遗传学和建模研究
  • 批准号:
    8502560
  • 财政年份:
    2012
  • 资助金额:
    $ 18.72万
  • 项目类别:

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    $ 18.72万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    $ 18.72万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    $ 18.72万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 18.72万
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    $ 18.72万
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    $ 18.72万
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    $ 18.72万
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    $ 18.72万
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    $ 18.72万
  • 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
  • 批准号:
    10534864
  • 财政年份:
    2023
  • 资助金额:
    $ 18.72万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了